MARKET

RVMD

RVMD

Revolution Medicines, Inc.
NASDAQ
79.64
+1.16
+1.48%
After Hours: 79.89 +0.25 +0.31% 19:54 12/05 EST
OPEN
78.48
PREV CLOSE
78.48
HIGH
79.82
LOW
77.89
VOLUME
1.71M
TURNOVER
--
52 WEEK HIGH
79.82
52 WEEK LOW
29.17
MARKET CAP
15.40B
P/E (TTM)
-15.3808
1D
5D
1M
3M
1Y
5Y
1D
Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue?
NASDAQ · 1d ago
Strategic Positioning and Potential of Revolution Medicines in Pancreatic Cancer Treatment
TipRanks · 2d ago
Promising Outlook for Revolution Medicines: Buy Rating Backed by Pivotal Trials and Market Potential
TipRanks · 4d ago
Weekly Report: what happened at RVMD last week (1124-1128)?
Weekly Report · 6d ago
How Are Recent Executive Share Sales Shaping Revolution Medicines' (RVMD) Standing in Oncology Innovation?
Simply Wall St · 6d ago
Revolution Medicines (RVMD): Examining Valuation as Analyst Support Boosts Interest in Pancreatic Cancer Pipeline
Simply Wall St · 11/28 21:27
Revolution Medicines CFO Jack Anders Reports Sale of Common Shares
Reuters · 11/26 21:17
Revolution Medicines Director and Officer Mark A. Goldsmith Reports Sale of Common Shares
Reuters · 11/26 21:16
More
About RVMD
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).

Webull offers Revolution Medicines Inc stock information, including NASDAQ: RVMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RVMD stock methods without spending real money on the virtual paper trading platform.